Last updated on April 18, 2014 at 16:34 EDT

Latest Salix Pharmaceuticals Stories

2008-11-03 12:00:26

Salix Pharmaceuticals, a specialty pharmaceutical company, has announced that the FDA has granted marketing approval for Apriso extended-release capsules 0.375gm. The approval is based on results from two randomized, double-blind, placebo-controlled multi-center, multi-national studies totaling 562 adults in remission from ulcerative colitis (UC). Apriso is a locally-acting aminosalicylate indicated for the maintenance of remission of UC adults. Additionally, Apriso is said to be the...

2008-07-01 06:00:49

Salix Pharmaceuticals has initiated patient enrollment in Target 1 and Target 2, its Phase III, randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of rifaximin 550mg, dosed three times daily, in the treatment of subjects with non-constipation irritable bowel syndrome. According to the company, two 600-subject trials will be conducted simultaneously in approximately 180 study centers throughout the US and Canada. Subjects will receive...